Lowest Price Guaranteed
Slides
103
Last Updated
March 2025
View Count
12713
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Cancer Immunotherapy
6.2.1. Key Characteristics of Cancer Immunotherapy
6.2.2. Key Applications of the Cancer Immunotherapy
6.2.3. Challenges Associated with Cancer Immunotherapy
6.3. Future Perspective
7. COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Cancer Immunotherapy Drug Developers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Cancer Immunotherapy Drugs: Overall Market Landscape
7.2.3.1. Analysis by Product Type
7.2.3.2. Analysis by Application Type
7.2.3.3. Analysis by Route of Administration Type
7.2.3.4. Analysis by Mechanism of Action Type
7.2.3.5. Analysis by Distribution Channel Type
7.2.3.6. Analysis by End Users
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies
8.4. Company Competitiveness Analysis: Cancer Immunotherapy Providers
8.4.1. Cancer Immunotherapy Drug Developers Based in North America (Peer Group 1)
8.4.2. Cancer Immunotherapy Drug Developers Based in Europe (Peer Group 2)
8.4.3. Cancer Immunotherapy Drug Developers Based in Asia-Pacific (Peer Group 3)
8.4.4. Cancer Immunotherapy Drug Developers Based in Middle East and North Africa, and Latin America (Peer Group 4)
8.5. Key Findings
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. AstraZeneca
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook
* Similar detail is presented for other below mentioned companies based on information in the public domain
9.3. Amgen
9.4. Atara Biotherapeutics
9.5. AbbVie
9.6. Bayer
9.7. Bristol-Myers Squibb
9.8. Celldex Therapeutics
9.9. Cellectis
9.10. Gilead Sciences
9.11. GSK
9.12. Eli Lilly
9.13. Immunocore
9.14. Incyte
9.15. Janssen Pharmaceutical
9.16. Merck
9.17. Novartis
9.18. Pfizer
9.19. Roche
10. SWOT ANALYSIS
11. MARKET IMPACT ANALYSIS
11.1. Chapter Overview
11.2. Market Drivers
11.3. Market Restraints
11.4. Market Opportunities
11.5. Market Challenges
11.6. Conclusion
12. GLOBAL CANCER IMMUNOTHERAPY MARKET
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Trends Disruption Impacting Market
12.4. Global Cancer Immunotherapy Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
12.5. Multivariate Scenario Analysis
12.5.1. Conservative Scenario
12.5.2. Optimistic Scenario
12.6. Key Market Segmentations
13. MARKET OPPORTUNITIES BASED ON TYPE OF PRODUCT
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Revenue Shift Analysis
13.4. Market Movement Analysis
13.5. Penetration-Growth (P-G) Matrix
13.6. Cancer Immunotherapy Market for Checkpoint Inhibitors: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.7. Cancer Immunotherapy Market for Cell Therapies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.8. Cancer Immunotherapy Market for Cancer Vaccines: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.9. Cancer Immunotherapy Market for Immune Modulators: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.10. Cancer Immunotherapy Market for Oncolytic Viral Therapies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.11. Cancer Immunotherapy Market for Monoclonal Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
13.12. Data Triangulation and Validation
14. MARKET OPPORTUNITIES BASED ON APPLICATION
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Revenue Shift Analysis
14.4. Market Movement Analysis
14.5. Penetration-Growth (P-G) Matrix
14.6. Cancer Immunotherapy Market for Breast Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.7. Cancer Immunotherapy Market for Colorectal Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.8. Cancer Immunotherapy Market for Head & Neck Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.9. Cancer Immunotherapy Market for Lung Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.10. Cancer Immunotherapy Market for Melanoma: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.11. Cancer Immunotherapy Market for Ovarian Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.12. Cancer Immunotherapy Market for Prostate Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.13. Cancer Immunotherapy Market for Pancreatic Cancer: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.14. Cancer Immunotherapy Market for Other Applications: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
14.15. Data Triangulation and Validation
15. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Cancer Immunotherapy Market for Intravenous (IV): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.7. Cancer Immunotherapy Market for Intramuscular: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.8. Cancer Immunotherapy Market for Oral: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.9. Data Triangulation and Validation
16. MARKET OPPORTUNITIES BASED ON MECHANISM OF ACTION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Cancer Immunotherapy Market for Immune Checkpoint Inhibitors: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.7. Cancer Immunotherapy Market for Tumor Antigen Targeted Therapy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.8. Cancer Immunotherapy Market for Cell Signaling Modulators: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.9. Cancer Immunotherapy Market for Immune Modulators: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.10. Data Triangulation and Validation
17. MARKET OPPORTUNITIES BASED ON TYPE OF DISTRIBUTION CHANNEL
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Cancer Immunotherapy Market for Hospital Pharmacies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.7. Cancer Immunotherapy Market for Retail Pharmacies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.8. Cancer Immunotherapy Market for Online Pharmacies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.9. Data Triangulation and Validation
18. MARKET OPPORTUNITIES BASED ON TYPE OF END USER
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Cancer Immunotherapy Market for Hospitals & Clinics: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.7. Cancer Immunotherapy Market for Cancer Research Centers: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.8. Cancer Immunotherapy Market for Other End Users: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.9. Data Triangulation and Validation
19. MARKET OPPORTUNITIES FOR CANCER IMMUNOTHERAPY IN NORTH AMERICA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. Cancer Immunotherapy Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.1. Cancer Immunotherapy Market in the US: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.2. Cancer Immunotherapy Market in Canada: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.6.3. Cancer Immunotherapy Market in Mexico: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.7. Data Triangulation and Validation
20. MARKET OPPORTUNITIES FOR CANCER IMMUNOTHERAPY IN EUROPE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Cancer Immunotherapy Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.1. Cancer Immunotherapy Market in Germany: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.2. Cancer Immunotherapy Market in France: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.3. Cancer Immunotherapy Market in Italy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.4. Cancer Immunotherapy Market in Spain: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.5. Cancer Immunotherapy Market in the UK: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.6. Cancer Immunotherapy Market in Rest of Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.7. Data Triangulation and Validation
21. MARKET OPPORTUNITIES FOR CANCER IMMUNOTHERAPY IN ASIA-PACIFIC
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Cancer Immunotherapy Market in Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.1. Cancer Immunotherapy Market in China: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.2. Cancer Immunotherapy Market in India: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.3. Cancer Immunotherapy Market in Japan: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.4. Cancer Immunotherapy Market in South Korea: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.5. Cancer Immunotherapy Market in Australia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.6. Cancer Immunotherapy Market in Russia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.7. Cancer Immunotherapy Market in Thailand: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.8. Cancer Immunotherapy Market in Malaysia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.9. Cancer Immunotherapy Market in Indonesia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.10. Cancer Immunotherapy Market in Rest of the Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.7. Data Triangulation and Validation
22. MARKET OPPORTUNITIES FOR CANCER IMMUNOTHERAPY IN MIDDLE EAST AND NORTH AFRICA (MENA)
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Cancer Immunotherapy Market in Middle East and North Africa (MENA): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.1. Cancer Immunotherapy Market in Egypt: Historical Trends (Since 2019) and Forecasted Estimates (Till 205)
22.6.2. Cancer Immunotherapy Market in Saudi Arabia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.3. Cancer Immunotherapy Market in United Arab Emirates (UAE): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.7. Data Triangulation and Validation
23. MARKET OPPORTUNITIES FOR CANCER IMMUNOTHERAPY IN LATIN AMERICA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. Cancer Immunotherapy Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
23.6.1. Cancer Immunotherapy Market in Argentina: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
23.6.2. Cancer Immunotherapy Market in Brazil: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
23.7. Data Triangulation and Validation
24. TABULATED DATA
25. LIST OF COMPANIES AND ORGANIZATIONS
26. CUSTOMIZATION OPPORTUNITIES
27. ROOTS SUBSCRIPTION SERVICES
28. AUTHOR DETAIL